Shares of TG Therapeutics Inc. (NASDAQ:TGTX) rose 3.6% during trading on Wednesday . The company traded as high as $5.89 and last traded at $5.83, with a volume of 150,496 shares changing hands. The stock had previously closed at $5.63.

TGTX has been the topic of a number of research analyst reports. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Thursday, April 14th. SunTrust Banks Inc. initiated coverage on shares of TG Therapeutics in a research report on Friday, May 27th. They set a “buy” rating and a $18.00 price target on the stock. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Brean Capital reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, May 31st. Finally, Roth Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a research report on Thursday, June 9th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. TG Therapeutics has an average rating of “Buy” and a consensus price target of $22.33.

The company’s market cap is $326.63 million. The stock has a 50-day moving average price of $6.62 and a 200-day moving average price of $8.19.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.08. Equities analysts forecast that TG Therapeutics Inc. will post ($1.15) earnings per share for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund increased its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned about 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent quarter.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.